• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放射诱导的乳腺血管肉瘤:一项回顾性病例系列研究的结果

Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series.

作者信息

Cohen-Hallaleh R B, Smith H G, Smith R C, Stamp G F, Al-Muderis O, Thway K, Miah A, Khabra K, Judson I, Jones R, Benson C, Hayes A J

机构信息

The Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK.

出版信息

Clin Sarcoma Res. 2017 Aug 7;7:15. doi: 10.1186/s13569-017-0081-7. eCollection 2017.

DOI:10.1186/s13569-017-0081-7
PMID:28794852
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5547463/
Abstract

BACKGROUND

Radiation induced angiosarcoma (RIAS) of the breast is a rare and aggressive complication of radiotherapy. Due to the rarity of this disease, much of the evidence for its management is based on case reports or small retrospective series. We sought to describe the management and outcomes of RIAS in a large single-institution series.

METHODS

All patients diagnosed with RIAS between January 2000 and January 2014 were identified from an institutional database.

RESULTS

A total of 49 patients were identified. Median age at diagnosis was 72 years (range 51-93). Median time from completion of radiotherapy to diagnosis of RIAS was 7.5 years. Median tumour size at presentation was 5.0 cm (1.5-19.0). The majority of patients presented with localised disease (47, 95.9%). Of these, 35 (74.5%) were suitable for surgery and underwent surgery with curative intent. Twelve patients presented with localised irresectable disease. Of these, 7 received systemic chemotherapy, with a sufficient response to facilitate surgery in 3 patients. Following potentially curative surgery, 2-year local recurrence-free was 55.2%. Survival was significantly prolonged in patients presenting with resectable disease (2-year overall survival 71.1% vs 33.3%, p < 0.001). Tumour size >5 cm was prognostic of distant metastases-free survival and overall survival.

CONCLUSION

RIAS are rare, aggressive soft-tissue lesions with limited treatment options and high-rates of both local and systemic relapse.

摘要

背景

乳腺放射性血管肉瘤(RIAS)是放疗罕见且侵袭性强的并发症。由于该疾病罕见,其治疗的许多证据基于病例报告或小型回顾性系列研究。我们试图在一个大型单机构系列研究中描述RIAS的治疗及预后。

方法

从机构数据库中识别出2000年1月至2014年1月期间所有诊断为RIAS的患者。

结果

共识别出49例患者。诊断时的中位年龄为72岁(范围51 - 93岁)。从放疗结束到诊断为RIAS的中位时间为7.5年。就诊时肿瘤的中位大小为5.0厘米(1.5 - 19.0厘米)。大多数患者表现为局限性疾病(47例,95.9%)。其中,35例(74.5%)适合手术并接受了根治性手术。12例患者表现为局限性不可切除疾病。其中,7例接受了全身化疗,3例有足够反应从而得以进行手术。在进行了可能根治性手术之后,2年局部无复发生存率为55.2%。可切除疾病患者的生存期显著延长(2年总生存率71.1%对33.3%,p < 0.001)。肿瘤大小>5厘米是无远处转移生存期和总生存期的预后指标。

结论

RIAS是罕见、侵袭性强的软组织病变,治疗选择有限,局部和全身复发率高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7029/5547463/d1f028aa66d4/13569_2017_81_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7029/5547463/a509de9570d2/13569_2017_81_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7029/5547463/d1f028aa66d4/13569_2017_81_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7029/5547463/a509de9570d2/13569_2017_81_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7029/5547463/d1f028aa66d4/13569_2017_81_Fig2_HTML.jpg

相似文献

1
Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series.放射诱导的乳腺血管肉瘤:一项回顾性病例系列研究的结果
Clin Sarcoma Res. 2017 Aug 7;7:15. doi: 10.1186/s13569-017-0081-7. eCollection 2017.
2
Radiation induced angiosarcoma of the breast: case series and review of the literature.放射性诱发的乳腺血管肉瘤:病例系列及文献综述
Facts Views Vis Obgyn. 2018 Dec;10(4):215-220.
3
Rare case of radiotherapy-induced angiosarcoma (RIAS) after conservative and radical treatment of breast cancer: About two cases and review of the literature.乳腺癌保守及根治性治疗后放疗诱发血管肉瘤(RIAS)的罕见病例:附两例报告并文献复习
Int J Surg Case Rep. 2024 Jan;114:109050. doi: 10.1016/j.ijscr.2023.109050. Epub 2023 Nov 21.
4
Recurring radiation-induced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report.复发性放射性诱发的乳腺血管肉瘤接受紫杉醇化疗的病例报告
Surg Case Rep. 2020 Jan 16;6(1):25. doi: 10.1186/s40792-020-0790-7.
5
Radiation-induced angiosarcoma of the breast: A case report.辐射诱发的乳腺血管肉瘤:一例报告。
Int J Surg Case Rep. 2024 Oct;123:110253. doi: 10.1016/j.ijscr.2024.110253. Epub 2024 Sep 10.
6
Radiation-induced angiosarcoma of the breast: a retrospective analysis of 15 years' experience at an oncology center.放疗诱发的乳腺血管肉瘤:肿瘤中心15年经验的回顾性分析
Radiol Bras. 2018 Sep-Oct;51(5):281-286. doi: 10.1590/0100-3984.2017.0129.
7
Clinicopathological features of breast angiosarcoma: A 16-years single-institution experience.乳腺血管肉瘤的临床病理特征:一项为期16年的单机构研究经验。
Int J Surg Case Rep. 2017;37:211-215. doi: 10.1016/j.ijscr.2017.06.040. Epub 2017 Jun 30.
8
Microsatellite-Stable Radiation-Induced Angiosarcoma after Breast-Conserving Surgery: A Case Report.保乳手术后微卫星稳定的辐射诱导血管肉瘤:一例报告
Case Rep Oncol. 2020 Oct 15;13(3):1275-1280. doi: 10.1159/000510809. eCollection 2020 Sep-Dec.
9
A retrospective review of 145 patients with angiosarcoma: Radiation therapy, extent of resection and chemotherapy are important predictors of survival.对145例血管肉瘤患者的回顾性研究:放射治疗、切除范围和化疗是生存的重要预测因素。
Mol Clin Oncol. 2020 Aug;13(2):179-185. doi: 10.3892/mco.2020.2055. Epub 2020 Jun 2.
10
Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution.骶骨脊索瘤:单一机构 30 年 101 例临床回顾。
Spine J. 2019 May;19(5):869-879. doi: 10.1016/j.spinee.2018.11.002. Epub 2018 Nov 14.

引用本文的文献

1
Acrometastasis of the Third Finger in Widespread Radiation-Induced Angiosarcoma.广泛放射性血管肉瘤中第三指的肢端转移
Int J Rheum Dis. 2025 Jun;28(6):e70324. doi: 10.1111/1756-185X.70324.
2
Lymph node involvement in secondary breast angiosarcoma - a case presentation.继发性乳腺血管肉瘤的淋巴结受累——一例报告。
Rom J Morphol Embryol. 2024 Jul-Sep;65(3):523-529. doi: 10.47162/RJME.65.3.15.
3
Radiation-Induced Breast Angiosarcoma-A Single-Institution Experience.放射性诱发的乳腺血管肉瘤——单机构经验

本文引用的文献

1
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.帕唑帕尼治疗晚期血管肉瘤:一项欧洲癌症研究与治疗组织软组织和骨肉瘤组(STBSG)的回顾性分析。
Acta Oncol. 2017 Jan;56(1):88-92. doi: 10.1080/0284186X.2016.1234068. Epub 2016 Nov 14.
2
Radiation-Associated Angiosarcoma of the Breast: Clinical and Pathologic Features.乳腺放射性相关血管肉瘤:临床与病理特征
Arch Pathol Lab Med. 2016 May;140(5):477-81. doi: 10.5858/arpa.2014-0581-RS.
3
Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: Determining tumor behavior prior to surgical resection.
Diagnostics (Basel). 2024 Oct 18;14(20):2326. doi: 10.3390/diagnostics14202326.
4
Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease.乳腺放射性相关血管肉瘤:一种罕见且侵袭性疾病的最新进展
J Pers Med. 2024 Aug 14;14(8):859. doi: 10.3390/jpm14080859.
5
Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective.癌症治疗中皮肤毒性的管理:澳大利亚/新西兰视角
Cancers (Basel). 2024 Jul 12;16(14):2526. doi: 10.3390/cancers16142526.
6
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.妇科肿瘤协作组《早期乳腺癌患者诊断与治疗建议:2024年更新》
Breast Care (Basel). 2024 Jun;19(3):165-182. doi: 10.1159/000538596. Epub 2024 Apr 18.
7
Magnetic resonance imaging findings of radiation-induced breast angiosarcoma: A case report.放射性诱发乳腺血管肉瘤的磁共振成像表现:一例报告
World J Clin Cases. 2024 May 6;12(13):2237-2242. doi: 10.12998/wjcc.v12.i13.2237.
8
UK guidelines for the management of soft tissue sarcomas.英国软组织肉瘤管理指南。
Br J Cancer. 2025 Jan;132(1):11-31. doi: 10.1038/s41416-024-02674-y. Epub 2024 May 11.
9
An Unexpected Late Recurrence of Breast Irradiation-Induced Angiosarcoma Following Autologous Microvascular Breast Reconstruction.自体微血管乳房重建术后乳房放疗诱发的血管肉瘤意外晚期复发
Cureus. 2024 Feb 23;16(2):e54741. doi: 10.7759/cureus.54741. eCollection 2024 Feb.
10
Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.放射性诱发的乳腺血管肉瘤:区域治疗中心的回顾性分析
Breast Cancer. 2024 Mar;31(2):272-282. doi: 10.1007/s12282-023-01535-5. Epub 2023 Dec 26.
原发性皮肤/软组织血管肉瘤的新辅助化疗:手术切除前确定肿瘤行为
J Surg Oncol. 2015 Jun;111(7):829-33. doi: 10.1002/jso.23891. Epub 2015 Mar 13.
4
Clinical management of secondary angiosarcoma after breast conservation therapy.保乳治疗后继发性血管肉瘤的临床管理
Rep Pract Oncol Radiother. 2013 Aug 23;19(1):37-46. doi: 10.1016/j.rpor.2013.07.013. eCollection 2014 Jan.
5
Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review.原发性乳腺癌放疗后相关性血管肉瘤(RAAS)的治疗和预后因素:系统综述。
Eur J Cancer. 2014 Jul;50(10):1779-1788. doi: 10.1016/j.ejca.2014.03.002. Epub 2014 Apr 11.
6
Thalidomide combined with neoadjuvant chemotherapy in angiosarcoma of the breast with complete pathologic response: case report and review of literature.沙利度胺联合新辅助化疗治疗完全病理缓解的乳腺血管肉瘤:病例报告及文献复习。
Breast Care (Basel). 2013 Mar;8(1):74-6. doi: 10.1159/000346822.
7
Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer.乳腺癌患者接受手术和放疗后,与放疗相关的乳腺血管肉瘤的长期预后。
Ann Surg Oncol. 2013 Apr;20(4):1267-74. doi: 10.1245/s10434-012-2755-y. Epub 2012 Dec 6.
8
Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO).局限性血管肉瘤:预后因素的确定和治疗效果的分析。法国肉瘤研究组(GSF/GETO)的回顾性分析。
Eur J Cancer. 2013 Jan;49(2):369-76. doi: 10.1016/j.ejca.2012.08.016. Epub 2012 Sep 8.
9
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.多柔比星、异环磷酰胺和粒细胞集落刺激因子辅助化疗治疗切除的软组织肉瘤(EORTC 62931):一项多中心随机对照试验。
Lancet Oncol. 2012 Oct;13(10):1045-54. doi: 10.1016/S1470-2045(12)70346-7. Epub 2012 Sep 4.
10
Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection.乳腺癌相关放射性血管肉瘤:尽管手术达到 R0 切除,但复发率高且生存预后差。
Ann Surg Oncol. 2012 Aug;19(8):2700-6. doi: 10.1245/s10434-012-2310-x. Epub 2012 Mar 31.